- Home
- GSUN vs RNAZ Comparison
GSUN vs RNAZ Comparison
Compare GSUN & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSUN
- RNAZ
- Stock Information
- Founded
- GSUN 1997
- RNAZ 2016
- Country
- GSUN China
- RNAZ United States
- Employees
- GSUN N/A
- RNAZ N/A
- Industry
- GSUN Other Consumer Services
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- GSUN Real Estate
- RNAZ Health Care
- Exchange
- GSUN Nasdaq
- RNAZ Nasdaq
- Market Cap
- GSUN 5.4M
- RNAZ 4.9M
- IPO Year
- GSUN 2022
- RNAZ 2021
- Fundamental
- Price
- GSUN $2.98
- RNAZ $3.35
- Analyst Decision
- GSUN
- RNAZ Strong Buy
- Analyst Count
- GSUN 0
- RNAZ 1
- Target Price
- GSUN N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- GSUN 9.2K
- RNAZ 143.7K
- Earning Date
- GSUN 02-05-2025
- RNAZ 11-14-2024
- Dividend Yield
- GSUN N/A
- RNAZ N/A
- EPS Growth
- GSUN N/A
- RNAZ N/A
- EPS
- GSUN N/A
- RNAZ N/A
- Revenue
- GSUN $6,336,931.00
- RNAZ N/A
- Revenue This Year
- GSUN N/A
- RNAZ N/A
- Revenue Next Year
- GSUN N/A
- RNAZ N/A
- P/E Ratio
- GSUN N/A
- RNAZ N/A
- Revenue Growth
- GSUN N/A
- RNAZ N/A
- 52 Week Low
- GSUN $2.21
- RNAZ $2.66
- 52 Week High
- GSUN $11.20
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- GSUN 54.39
- RNAZ 30.32
- Support Level
- GSUN $2.64
- RNAZ $2.90
- Resistance Level
- GSUN $2.94
- RNAZ $3.50
- Average True Range (ATR)
- GSUN 0.19
- RNAZ 0.42
- MACD
- GSUN 0.03
- RNAZ 0.31
- Stochastic Oscillator
- GSUN 93.02
- RNAZ 50.74
About GSUN Golden Sun Education Group Limited
Golden Sun Health Technology Group Ltd is engaged in the provision of education and management services in the People's Republic of China. It offers tutorial centers for children and adults, one educational company that partners with high schools to offer language classes to their students, and one logistics company that provides logistic and consulting services. The company operates in two segments; Education segment and the Wellness segment. Majority of the revenue is generated from the Education segment which offers foreign language tutorial services and other education training management services in China. The wellness segment offers wellness service and related products.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.